As previously reported, Scotiabank downgraded Myriad Genetics (MYGN) to Sector Perform from Outperform with a price target of $6, down from $20. While the firm continues to believe there is opportunity for Myriad to execute against its Oncology and Women’s Health business ambitions over the next several years, 2025 is likely to be “a transitional year,” the analyst tells investors in a research note. The firm would like to see tangible and consistent progress and also waits for a potential strategy reset under the new CEO before turning more positive on shares, the analyst added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics downgraded to Sector Perform from Outperform at Scotiabank
- Myriad Genetics price target lowered to $4 from $9 at BofA
- Myriad Genetics price target lowered to $7 from $16 at Morgan Stanley
- Myriad Genetics price target lowered to $9 from $12.50 at Piper Sandler
- Hold Rating Maintained for Myriad Genetics Amid Revenue Cuts and Strategic Uncertainty